KETOFEN®
(ketoprofen)

Sterile Solution, 100 mg/mL

For intravenous use in horses only.

CAUTION

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

Ketoprofen is a non-steroidal antiinflammatory agent of the propionic acid class that includes ibuprofen, naproxen and fenoprofen. Each mL of KETOFEN (ketoprofen) contains 100 mg of ketoprofen in an aqueous formulation containing: L-Arginine, 70 mg; citric acid (to adjust pH); benzyl alcohol, 0.025 g (as preservative).

It is packaged in a multiple dose bottle.

PHARMACOLOGY

KETOFEN is a non-narcotic, non-steroidal anti-inflammatory agent with analgesic and antipyretic properties.

In horses, intravenous dosages of ketoprofen ranging from 0.5 to 1.5 mg/lb resulted in dosage dependent anti-inflammatory effects in the chronic adjuvant carpitis model as depicted in the following graph.

| MAXIMUM FLEXION (intravenous ketoprofen, mean ± sem, n = 4)* |
Additional studies using the same model in horses have shown that the effects of ketoprofen are maximal by 12 hours and still measurable at 24 hours after each dosage as depicted in the following graph.

MAXIMUM FLEXION (mean ± sem, n = 6)*

\[ n = \text{number of animals} \]

\[ * \text{sem = standard error of the mean} \]
n = number of animals
* sem = standard error of the mean

TOXICITY
Horses were found to tolerate ketoprofen given intravenously at dosages of 0, 1, 3 and 5 mg/lb once daily for 15 consecutive days (up to five times the recommended dosage for three times the usual duration) with no evidence of toxic effects. In clinical studies, intravenous injection of 1 mg/lb/day for five days resulted in no injection site irritation or other side effects.

At 15-fold overdose (15 mg/lb/day) for five days one of two horses developed severe laminitis, but no gross lesions or histologic changes were observed. The toxic effects observed in the horses given a 25-fold overdose (25 mg/lb/day) for five days included inappetence, depression, icterus, abdominal swelling and postmortem findings of gastritis, nephritis and hepatitis.

INDICATION
KETOFEN® (ketoprofen) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

ADMINISTRATION AND DOSAGE
The recommended dosage is 1 mg/lb (1 mL/100 lbs) of body weight once daily. Treatment is administered by intravenous injection and may be repeated for up to five days. Onset of activity is within two hours with peak response by 12 hours.

CONTRAINDICATIONS
There are no known contraindications to this drug when used as directed.
Intra-arterial injection should be avoided.
Do not use in a horse if it has previously shown hypersensitivity to ketoprofen.
CAUTION
This product should not be used in breeding animals since the effects of KETOFEN on fertility, pregnancy or fetal health in horses have not been determined.

PRECAUTIONS
Studies to determine activity of KETOFEN when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.

WARNING
Do not use in horses intended for human consumption.

SIDE EFFECTS
During investigational studies, no significant side effects were reported.

HOW SUPPLIED
KETOFEN (ketoprofen) Solution 100 mg/mL is available in 50 mL and 100 mL multidose bottles.

Store below 25°C (77°F), with brief excursions permitted between 0°C - 40°C (32°F - 104°F). Use contents within 4 months of first vial puncture.

NADA 140-269, Approved by FDA
Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007
Made in Spain
January 2015
PRINCIPAL DISPLAY PANEL - 100 mL Bottle Carton

KETOFEN®
(ketoprofen)
Sterile Solution
100 mg/mL
For intravenous use in horses only.
100 mL Multiple Dose Bottle

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
**KETOFEN**
ketoprofen injection, solution

<table>
<thead>
<tr>
<th>Product Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Type</strong></td>
<td>PRESCRIPTION ANIMAL DRUG</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>INTRAVENOUS</td>
</tr>
</tbody>
</table>
## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>KETOPROFEN (UNII: 90Y4QC304K) (KETOPROFEN - UNII:90Y4QC304K)</td>
<td>KETOPROFEN</td>
<td>100 mg in 1 mL</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARGININE (UNII: 94ZLA3W45F)</td>
<td>70 mg in 1 mL</td>
</tr>
<tr>
<td>CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)</td>
<td></td>
</tr>
<tr>
<td>BENZYL ALCOHOL (UNII: LKG8494WBH)</td>
<td></td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:5477-4396-1</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:5477-4396-2</td>
<td>50 mL in 1 BOTTLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:5477-4396-1</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:5477-4396-2</td>
<td>100 mL in 1 BOTTLE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NADA</td>
<td>NADA140269</td>
<td>09/26/1990</td>
<td></td>
</tr>
</tbody>
</table>

## Labeler

Zoetis Inc. (828851555)

Revised: 12/2016